Insurers bet on new type of job-based health benefits
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
Young Oncologists Scared of Academia’s Demands: Expert Speaks Out
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
The 340B ‘Saga’ Continued: HRSA, States, and Drug Manufacturers Contest 340B Contract Pharmacy Restrictions in Court
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
U.S. states with the highest prescription drug spend
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
CMS Needs to Do a Better Job With Value-Based Care, Experts Tell House Panel
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
Health inequities haven’t improved in last two decades, report says
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
New York Times Sues HRSA To Release 340B Data, Communications Between Office of Pharmacy Affairs and Apexus Leaders; Information Could Be Released Soon GalleryNew York Times Sues HRSA To Release 340B Data, Communications Between Office of Pharmacy Affairs and Apexus Leaders; Information Could Be Released Soon
New York Times Sues HRSA To Release 340B Data, Communications Between Office of Pharmacy Affairs and Apexus Leaders; Information Could Be Released Soon
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
Cancer Drug Shortages Impact Clinical Trials
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
Democratic senator calls on HHS to investigate PBMs blocking access to generic cancer drug
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
Biden administration touts lower costs for 64 prescription drugs
There’s a glaring shortage of injectable cancer drugs in market circulation, all because manufacturers are unable to make money off of them, experts told a U.S. House subcommittee last week.
